Business
Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the second quarter 2025, in conjunction with their partner Biogen's second quarter report. In total, sales of JPY 23.1 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 162.5 million which is an increase of approximately 280 percent compared to the royalty obtained by BioArctic in Q2 2024.
About this update from Eisai Co., Ltd.
[{"type":"text","content":"STOCKHOLM, July 31, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the second quarter 2025, in conjunction with their partner Biogen's second quarter report. In total, sales of JPY 23.1 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 162.5 million which is an increase of approximately 280 percent compared to the royalty obtained by BioArctic in Q2 2024. ","length":511,"tagName":"p"},{"type":"text","content":"The results included a one-time stockpiling effect in the Chinese market of around JPY 5.3 billion in response to the risk of tariffs. Total global sales excluding the stockpiling effect were approximately JPY 17.8 billion corresponding to royalty revenue of about SEK 125 million.","length":281,"tagName":"p"},{"type":"text","content":"BioArctic's report for the second quarter 2025 will be published on August 28 at 08:00 a.m. CET.","length":100,"tagName":"p"},{"type":"text","content":"This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on July 31, 2025, at 12:00 CET.","length":255,"tagName":"p"},{"type":"text","content":"For further information, please contact: Oskar Bosson, VP Communications and Investor RelationsE-mail: [email protected] Telephone: +46 704 107 180","length":164,"tagName":"p"},{"type":"text","content":"About lecanemab (Leqembi®)","length":26,"tagName":"p"},{"type":"text","content":"Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in 46 countries including the U.S., Japan, China, and the European Union for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD), and is under regulatory review in 10 countries","length":565,"tagName":"p"},{"type":"text","content":"Since July 2020, Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab...